Jim Klostergaard
Affiliations: | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular Biology, OncologyGoogle:
"Jim Klostergaard"Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Liang Y, Yu D, Perez-Soler R, et al. (2017) TRIB2 contributes to cisplatin resistance in small cell lung cancer. Oncotarget. 8: 109596-109608 |
Sahin IH, Klostergaard J. (2015) CD44 as a drug delivery target in human cancers: where are we now? Expert Opinion On Therapeutic Targets. 19: 1587-91 |
Lee SJ, Ghosh SC, Han HD, et al. (2012) Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4114-21 |
Klostergaard J, Seeney CE. (2012) Magnetic nanovectors for drug delivery. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: S37-50 |
Ghosh SC, Neslihan Alpay S, Klostergaard J. (2012) CD44: a validated target for improved delivery of cancer therapeutics. Expert Opinion On Therapeutic Targets. 16: 635-50 |
Klostergaard J, Seeney CE. (2012) Magnetic nanovectors for drug delivery. Maturitas. 73: 33-44 |
Seeney C, Ojwang JO, Weiss RD, et al. (2012) Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: history and current status. Nanomedicine (London, England). 7: 289-99 |
Chen X, Fokt I, Skora S, et al. (2012) Abstract C65: Drug-tolerant cancer cells show reduced tumor-initiating capacity: Depletion of CD44+ cells and evidence for epigenetic mechanisms Cancer Research. 72: C65-C65 |
Yan H, Chen X, Zhang Q, et al. (2011) Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. Plos One. 6: e24397 |
Galer CE, Sano D, Ghosh SC, et al. (2011) Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism Oral Oncology. 47: 1039-1047 |